HighVista Strategies LLC Trims Stake in Johnson & Johnson (JNJ)
HighVista Strategies LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 25.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,200 shares of the company’s stock after selling 1,400 shares during the period. HighVista Strategies LLC’s holdings in Johnson & Johnson were worth $556,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Harding Loevner LP acquired a new position in Johnson & Johnson in the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. Lenox Wealth Advisors Inc. lifted its stake in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in Johnson & Johnson in the second quarter valued at approximately $177,000. Finally, Ullmann Financial Group Inc. acquired a new position in Johnson & Johnson in the first quarter valued at approximately $186,000. Institutional investors own 65.89% of the company’s stock.
JNJ has been the topic of several recent analyst reports. J P Morgan Chase & Co boosted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research note on Wednesday, August 16th. Jefferies Group set a $145.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research note on Tuesday, August 15th. Cowen set a $147.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, August 24th. UBS reissued an “underweight” rating on shares of Johnson & Johnson in a research note on Thursday, August 24th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $145.00 price target on shares of Johnson & Johnson in a research note on Friday, September 1st. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $144.59.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the prior year, the company posted $1.68 earnings per share. Johnson & Johnson’s revenue was up 10.3% compared to the same quarter last year. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.39%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.
ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/12/11/highvista-strategies-llc-trims-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.